Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Predictive markers of efficacy for an angiopoietin-2 targeting therapeutic in xenograft models.

PloS one - 1 Jan 2013

Triana-Baltzer Gallen, Pavlicek Adam, Goulart Ariadne, Huang Hanhua, Pirie-Shepherd Steven, Levin Nancy

Abstract excerpt

The clinical efficacy of anti-angiogenic therapies has been difficult to predict, and biomarkers that can predict responsiveness are sorely needed in this era of personalized medicine. CVX-060 is an angiopoietin-2 (Ang2) targeting therapeutic, consisting of two peptides that bind Ang2 with high affinity and specificity, covalently fused to a scaffold antibody. In order to optimize the use of this compound in the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors
Share to Angiopoietin-1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Angiopoietin-2

Share to Basigin

Share to Biomarkers, Pharmacological

Share to Epidermal Growth Factor

Share to Tumor Burden

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 24244628
DOI: 10.1371/journal.pone.0080132
PMCID: PMC3828186

Genes

EGF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Predictive markers of efficacy for an angiopoietin-2 targeting therapeutic in xenograft models.PMID 24244628Read ↗

Biomarkers of angiogenesis and their role in the development of VEGF inhibitors.Semantic proximity Read ↗

Clinical translation of angiogenesis inhibitorsSemantic proximity Read ↗

Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance).Semantic proximity Read ↗

Targeting tumour vasculature by inhibiting activin receptor-like kinase (ALK)1 functionSemantic proximity Read ↗

Vascular phenotype identification and anti-angiogenic treatment recommendation: A pseudo-multiscale mathematical model of angiogenesis.Semantic proximity Read ↗

Anti-VEGF therapy: higher potency and long-lasting antagonism are not necessarily betterSemantic proximity Read ↗

VEGFA gene variants are associated with breast cancer progression.Semantic proximity Read ↗

Progress in antiangiogenic gene therapy of cancerSemantic proximity Read ↗

Hypoxia-Inducible Factor-1 Target Genes as Indicators of Tumor Vessel Response to Vascular Endothelial Growth Factor InhibitionSemantic proximity Read ↗

Younger Age Is Associated with Favorable Outcomes in Adult Dogs with Hemangiosarcoma Receiving Adjuvant Doxorubicin Chemotherapy: Results from the PRO-DOX StudySemantic proximity Read ↗

Angiostatin: a circulating endothelial cell inhibitor that suppresses angiogenesis and tumor growth.Semantic proximity Read ↗

Identification of key residues involved in mediating the in vivo anti-tumor/anti-endothelial activity of Alphastatin.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.